In part 3 of a Spotlight special series on the role of new weight loss medicines like Ozempic in South Africa, we ask what these breakthrough jabs might mean for people living with HIV in the country. There is some tantalising early research on potential benefits, but also many uncertainties. Catherine Tomlinson reports.
In South Africa, access to weight loss medicines like Ozempic and Mounjaro remains limited to those who can shell out a few thousand Rand a month. In the second article of a Spotlight special series, Catherine Tomlinson looks at the medical need for these medicines in the country and what it would take for government to provide them in the public sector.
The obesity epidemic will hit South Africa hard on top of our high HIV burden, but advocate researcher and scientist Dr Nomathemba Chandiwana says she is ready to fight back harder. She speaks to Ufrieda Ho about her journey from working in state hospitals to transitioning into obesity medicine, and her move to Cape Town.
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, access to these medicines remain limited in South Africa. Catherine Tomlinson asks which of the GLP-1 agonists are available here and at what price.
Obesity is a public health crisis in South Africa, similar to HIV in the late 1990s, Dr Nomathemba Chandiwana tells Spotlight on the sidelines of the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. She also presented research that found lifestyle behaviour changes had a limited effect on reversing weight gain in people living with HIV.
